07:00 , Oct 19, 2015 |  BC Week In Review  |  Company News

Adheron, Roche deal

Roche will acquire Adheron, a developer of technology that disrupts cell adhesion via cell surface protein cadherin 11 ( Cad-11; CDH11). Adheron is investigating therapies for inflammatory and autoimmune disorders, including rheumatoid arthritis...
01:32 , Oct 10, 2015 |  BC Extra  |  Company News

Roche to acquire Adheron

Roche (SIX:ROG; OTCQX:RHHBY) will acquire Adheron Therapeutics Inc. (Berkeley, Calif.), a developer of technology that disrupts cell adhesion via cell surface protein Cadherin 11 ( Cad-11; CDH11). Adheron is investigating therapies for inflammatory and autoimmune...
07:00 , May 28, 2015 |  BC Innovations  |  Targets & Mechanisms

Joint attack

A newly discovered pathway that causes joint erosion in rheumatoid arthritis could lead to a new class of therapies that act locally in cells of the synovial lining and avoid the drawbacks of immunosuppressants. The pathway...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Clinical News

SDP051: Phase I data

A placebo-controlled Phase I trial in healthy volunteers showed that single ascending-doses of SDP051 were well tolerated up to 10 mg/kg with no evidence of significant adverse events. Next year, Adheron plans to start a...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Adheron board of directors update

Adheron Therapeutics Inc., Medford, Mass.   Business: Autoimmune   Appointed: Robert Baltera as executive chairman, formerly CEO of Amira Pharmaceuticals Inc., which Bristol-Myers Squibb Co. acquired   ...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Adheron management update

Adheron Therapeutics Inc., Medford, Mass.   Business: Autoimmune   Hired: Hari Kumar as CEO   ...